Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $194.6 million.

  • UroGen Pharma's Cash from Financing Activities fell 79.11% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 95.54%. This contributed to the annual value of $194.6 million for FY2024, which is 66.44% up from last year.
  • Per UroGen Pharma's latest filing, its Cash from Financing Activities stood at $194.6 million for FY2024, which was up 66.44% from $116.9 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Cash from Financing Activities ranged from a high of $194.6 million in FY2024 and a low of $16.5 million during FY2020.
  • Moreover, its 3-year median value for Cash from Financing Activities was $116.9 million (2023), whereas its average is $136.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 90.00% in 2020, then surged by 337.58% in 2021.
  • UroGen Pharma's Cash from Financing Activities (Yearly) stood at $16.5 million in 2020, then soared by 337.58% to $72.3 million in 2021, then spiked by 34.31% to $97.1 million in 2022, then climbed by 20.38% to $116.9 million in 2023, then soared by 66.44% to $194.6 million in 2024.